Fluorescence in situ hybridization and immunohistochemical analysis of p53 expression in endometrial cancer: Prognostic value and relation to ploidy

Annals of Surgical Oncology

Volumn 15, Issue 2, 2008, Pages 484-492

  Graesslin, Olivier ^a,b,c   Chantot Bastaraud, Sandra ^a   Lorenzato, Marianne ^c   Birembaut, Philippe ^c   Quéreux, Christian ^c   Daraï, Emile ^a,b  

^a HÔPITAL TENON   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c REIMS UNIVERSITY HOSPITAL   (France)

Author keywords

Endometrial cancer; FISH; Immunohistochemistry; p53; Ploidy; Tumor suppressor gene

Indexed keywords

PROTEIN P53;

ARTICLE; CANCER INVASION; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; ENDOMETRIUM CARCINOMA; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HETEROZYGOSITY; HISTOLOGY; HUMAN; HUMAN TISSUE; IMAGING; IMMUNOHISTOCHEMISTRY; LYMPH NODE; METASTASIS; MYOMETRIUM; PLOIDY; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; COMPARATIVE STUDY; ENDOMETRIUM TUMOR; GENETICS; HETEROZYGOSITY LOSS; METABOLISM; PATHOLOGY;

ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LOSS OF HETEROZYGOSITY; MYOMETRIUM; NEOPLASM INVASIVENESS; PLOIDIES; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 40649108858     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-007-9712-1     Document Type: Article

References (49)

1. Cook LS, Kmet LM, Magliocco AM, et al. Endometrial cancer survival among U.S. black and white women by birth cohort. Epidemiology 2006; 17:469-72
2. Rose PG. Endometrial carcinoma. N Engl J Med 1996; 335:640-9
3. Fisher B, Costantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994; 86:527-37
4. Mignotte H, Lasset C, Bonadona V, et al. Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. FNCLCC. Int J Cancer 1998; 76:325-30
5. Watson P, Vasen HF, Mecklin JP, et al. The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer. Am J Med 1994; 96:516-20
6. May P, May E. Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene 1999; 18:7621-36
7. Drane P, Bravard A, Bouvard V, et al. Reciprocal downregulation of p53 and SOD2 gene expression: implication in p53 mediated apoptosis. Oncogene 2001; 20:430-9
8. Mariani A, Sebo TJ, Webb MJ, et al. Molecular and histopathologic predictors of distant failure in endometrial cancer. Cancer Detect Prevent 2003; 27:434-41
9. Alkushi A, Lim P, Coldman A, et al. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level. Int J Gynaecol Pathol 2004; 23:129-37
10. Coronado PJ, Vidart JA, Lopez-Asenjo JA. P53 overexpression predicts endometrial carcinoma better than HER-2/neu overexpression. Eur J Obstet Gynecol Reprod Biol 2001; 98:103-8
11. Ragni N, Ferrero S, Prefumo F, et al. The association between p53 expression, stage and histological features in endometrial cancer. Eur J Obstet Gynecol Reprod Biol 2005; 123:111-6
12. Kounelis S, Kapranos N, Kouri E, et al. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature. Mod Pathol 2000; 13:379-88
13. Davidoff AM, Humphrey PA, Iglehart JD, et al. Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci USA 1991; 88:5006-10
14. Iggo R, Gatter K, Bartek J, et al. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990; 335:675-9
15. Hall PA, Lane DP. P53 in tumour pathology: can we trust immunohistochemistry? J Pathol 1994; 172:1-4
16. Soong R, Knowles S, Williams KE, et al. Overp53 expression protein is an independent prognostic indicator in human endometrial carcinoma. Br J Cancer 1996; 74:562-7
17. Taskin M, Lallas TA, Barber HR, et al. bcl-2 and p53 in endometrial adenocarcinoma. Mod Pathol 1997; 10:728-34
18. Erdem O, Erdem M, Dursun A, et al. Angiogenesis, p53, and bcl-2 expression as prognostic factors in endometrial cancer: comparison with traditional clinicopathological variables. Int J Gynecol Pathol 2003; 22:254-60
19. Zheng W, Cao P, Zheng M, et al. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes. Gynecol Oncol 1996; 61:167-74
20. Ito K, Watanabe K, Nasim S, et al. Prognostic significance of p53 overexpression in endometrial cancer. Cancer Res 1994; 54:4667-70
21. Williams JA Jr, Wang ZR, Parrish RS, et al. Fluorescence in situ hybridization analysis of Her-2/neu, c-myc and p53 in endometrial cancer. Exp Mol Pathol 1999; 67:135-43
22. Sandberg AA. Cancer cytogenetics for clinicians. Ca Cancer J Clin 1994; 44:136-59
23. Lim P, Aquino-Parsons CF, Wong F, et al. Low-risk endometrial carcinoma: assessment of a treatment policy based on tumor ploidy and identification of additional prognostic indicators. Gynecol Oncol 1999; 73:191-5
24. Santala M, Talvensaari-Mattila A. DNA ploidy is an independent prognostic indicator of overall survival in stage I endometrial endometrioid carcinoma. Anticancer Res 2003; 23:5191-96
25. Benedet JL, Bender H, Jones H 3rd, et al. FIGO staging classifications and clinical practice guidelines in the management of gynaecologic cancers. FIGO committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000; 70:209-62
26. Kallioniemi A, Kallioniemi OP, Waldman FM, et al. Detection of retinoblastoma gene copy number in metaphase chromosomes and interphase nuclei by fluorescence in situ hybridization. Cytogenet Cell Genet 1992; 60:190-3
27. De Jong JS, Van Diest PJ, Baak JPA. Methods in laboratory investigation. Heterogeneity and reproducibility of microvessel counts in breast cancer. Lab Invest 1995; 73:922-6
28. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 1995; 147:9-19
29. Matias-Guiu X, Catasus L, Bussaglia E, et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 2001; 32:569-77
30. Tashiro H, Isacson C, Levine R, et al. P53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997; 150:177-85
31. Jovanovic AS, Boynton KA, Mutter GL. Uteri of women with endometrial carcinoma contain a histopathologic spectrum of monoclonal putative precancers, some with microsatellite instability. Cancer Res 1996; 56:1917-21
32. Oehler MK, Brand A, Wain GV. Molecular genetics and endometrial cancer. J Br Menopause Soc 2003; 9:27-31
33. Inoue M, Okayama A, Fujita M, et al. Clinicopathological characteristics of p53 overexpression in endometrial cancers. Int J Cancer 1994; 58:14-9
34. Lukes AS, Kohler MF, Pieper CF, et al. Multivariable analysis of DNA ploidy, P53, and HER-2/NEU as prognostic factors in endometrial cancer. Cancer 1994; 73:2380-5
35. Leong AS-Y. Quantitation in immunohistology: fact or fiction? Appl Immunohistochem Mol Morphol 2004; 12:1-7
36. McCluggage WG, Connolly LE, McGregor G, et al. A strategy for defining biologically relevant levels of p53 protein expression in clinical samples with reference to endometrial neoplasia. Int J Gynecol Pathol 2005; 24:307-12
37. Nenutil R, Smardova J, Pavlova S, et al. Discriminating functional and non functional p53 in human tumours by p53 and MDM2 immunohistochemistry. J Pathol 2005; 207:251-9
38. Wynford-Thomas D. P53 in tumour pathology: can we trust immunohistochemistry? J Pathol 1992; 166:329-30
39. Soussi T, Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nature Rev Cancer 2001; 1:233-40
40. Soussi T, Kato S, Levy PP, et al. Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations. Hum Mutat 2005; 25:6-17
41. Ludwig RL, Bates S, Vousden KH. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol Cell Biol 1996; 16:4952-60
42. Semczuk A, Marzec B, Skomra D, et al. Allelic loss at TP53 is not related to p53 protein overexpression in primary human endometrial carcinomas. Oncology 2005; 69:317-25
43. Stewart RL, Royds JA, Burton JL, et al. Direct sequencing of the p53 gene shows absence of mutations in endometrioid endometrial adenocarcinomas expressing p53 protein. Histopathology 1998; 33:440-5
44. Coleman RL, Schinck JC, Miller DS, et al. DNA flow cytometric analysis of clinical stage I endometrial carcinomas with lymph node metastases. Gynecol Oncol 1993; 50:20-4
45. Terada K, Mattson D, Goo D, et al. DNA aneuploidy is associated with increased mortality for stage I endometrial cancer. Gynecol Oncol 2004; 95:483-7
46. Lundgren C, Auer G, Frankendal B, et al. Prognostic factors in surgical stage I endometrial carcinoma. Acta Oncol 2000; 43:49-56
47. Orbo A, Rydningen M, Straume B, et al. Significance of morphometric, DNA cytometric features, and other prognostic markers on survival of endometrial cancer patients in Northern Norway. Int J Gynecol Cancer 2002; 12:49-56
48. Biesterfeld S, Leitloff M, Rath W, et al. DNA image cytometry in the differential diagnosis of endometrial hyperplasia and adenocarcinoma. Analyt Quant Cytol Histol 2001; 23:123-8
49. Osmanagaoglu MA, Kadioglu S, Osmanagaoglu S, et al. The relationship between mutant p53 gene, DNA contents and conventional clinicopathological prognostic variables in cases with endometrial carcinoma. Eur J Gynaecol Oncol 2005; 26:64-70